1. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA,
Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al:
Nivolumab plus ipilimumab in advanced melanoma. N Engl J
Med 369: 122‑133, 2013.
2. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C,
Bellmunt J, Burris HA, Petrylak DP, Teng SL, et al: MPDL3280A
(anti‑PD‑L1) treatment leads to clinical activity in metastatic
bladder cancer. Nature 515: 558‑562, 2014.
3. Herbst RS, Baas P, Kim DW, Felip E, Pérez‑Gracia JL, Han JY,
Molina J, Kim JH, Arvis CD, Ahn MJ, et al: Pembrolizumab
versus docetaxel for previously treated, PD‑L1‑positive, advanced
non‑small‑cell lung cancer (KEYNOTE‑010): A randomised
controlled trial. Lancet 387: 1540‑1550, 2016.
4. Alexandrov LB, Nik‑Zainal S, Wedge DC, Aparicio SA,
Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A,
Børresen‑Dale AL, et al: Signatures of mutational processes in
human cancer. Nature 500: 415‑421, 2013.
5. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA,
Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, et al:
Prognostic value of tumor‑infiltrating lymphocytes in
triple‑negative breast cancers from two phase III randomized
adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.
J Clin Oncol 32: 2959‑2966, 2014.
6. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F,
Rouas G, Francis P, Crown JP, Hitre E, et al: Prognostic and
predictive value of tumor‑infiltrating lymphocytes in a phase III
randomized adjuvant breast cancer trial in node‑positive breast
cancer comparing the addition of docetaxel to doxorubicin with
doxorubicin‑based chemotherapy: BIG 02‑98. J Clin Oncol 31:
860‑867, 2013.
7. Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D,
Kellokumpu‑Lehtinen PL, Bono P, Kataja V, Desmedt C, et al:
Tumor infiltrating lymphocytes are prognostic in triple negative
breast cancer and predictive for trastuzumab benefit in early
breast cancer: Results from the FinHER trial. Ann Oncol 25:
1544‑1550, 2014.
8. Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M,
Nanda R, Winer EP, Mukai H, Tamura K, Armstrong A, et al:
Pembrolizumab monotherapy for previously untreated,
PD‑L1‑positive, metastatic triple‑negative breast cancer: Cohort
B of the phase II KEYNOTE‑086 study. Ann Oncol 30: 405‑411,
2019.
9. Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM,
Kuter I, Nanda R, Cassier PA, Delord JP, et al: Long‑term clinical
outcomes and biomarker analyses of atezolizumab therapy for
patients with metastatic triple‑negative breast cancer: A phase 1
study. JAMA Oncol 5: 74‑82, 2019.
10. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH,
Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, et al:
Atezolizumab and nab‑paclitaxel in advanced triple‑negative
breast cancer. N Engl J Med 379: 2108‑2121, 2018.
11. Teng MW, Ngiow SF, Ribas A and Smyth MJ: Classifying
cancers based on T‑cell Infiltration and PD‑L1. Cancer Res 75:
2139‑2145, 2015.
12. Emens LA, Loi S, Rugo HS, Schneeweiss A, Diéras V, Iwata H,
Barrios CH, Nechaeva M, Molinero L, Duc AN, et al: Abstract
GS1‑04: IMpassion130: Efficacy in immune biomarker subgroups
from the global, randomized, double‑blind, placebo‑controlled,
phase III study of atezolizumab + nab‑paclitaxel in patients with
treatment‑naïve, locally advanced or metastatic triple‑negative
breast cancer. Cancer Res 79 (4 Suppl): GS1‑04, 2019.
13. Noy R and Pollard JW: Tumor‑associated macrophages: From
mechanisms to therapy. Immunity 41: 49‑61, 2014.
14. DeNardo DG and Ruffell B: Macrophages as regulators of
tumour immunity and immunotherapy. Nat Rev Immunol 19:
369‑382, 2019.
15. Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL,
Luo J, Wang‑Gillam A, Goedegebuure SP, Linehan DC and
DeNardo DG: CSF1/CSF1R blockade reprograms tumor‑
infiltrating macrophages and improves response to T‑cell
checkpoint immunotherapy in pancreatic cancer models. Cancer
Res 74: 5057‑5069, 2014.
16. A rlauckas SP, Ga r r is CS, Koh ler R H, K it aoka M,
Cuccarese MF, Yang KS, Miller MA, Carlson JC, Freeman GJ,
Anthony RM, et al: In vivo imaging reveals a tumor‑associated
macrophage‑mediated resistance pathway in anti‑PD‑1 therapy.
Sci Transl Med 9: eaal3604, 2017.
17. Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M,
Centonze G, Ferro S, Ganzinelli M, Gasparini P, Huber V, et al:
Antibody‑Fc/FcR interaction on macrophages as a mechanism
for hyperprogressive disease in non‑small cell lung cancer subse‑
quent to PD‑1/PD‑L1 blockade. Clin Cancer Res 25: 989‑999,
2019.
18. Medrek C, Pontén F, Jirström K and Leandersson K: The pres‑
ence of tumor associated macrophages in tumor stroma as a
prognostic marker for breast cancer patients. BMC Cancer 12:
306, 2012.
19. Miyasato Y, Shiota T, Ohnishi K, Pan C, Yano H, Horlad H,
Yamamoto Y, Yamamoto‑Ibusuki M, Iwase H, Takeya M and
Komohara Y: High density of CD204‑positive macrophages
predicts worse clinical prognosis in patients with breast cancer.
Cancer Sci 108: 1693‑1700, 2017.
10
NAGANO et al: CD204+ MACROPHAGES ACCUMULATE IN TIL+PD‑L1+ BREAST CANCER
20. Shimada H, Hasebe T, Sugiyama M, Shibasaki S, Sugitani I,
Ueda S, Gotoh Y, Yasuda M, Arai E, Osaki A and Saeki T:
Fibrotic focus: An important parameter for accurate prediction
of a high level of tumor‑associated macrophage infiltration in
invasive ductal carcinoma of the breast. Pathol Int 67: 331‑341,
2017.
21. Hatogai K, Kitano S, Fujii S, Kojima T, Daiko H, Nomura S,
Yoshino T, Ohtsu A, Takiguchi Y, Doi T and Ochiai A:
Comprehensive immunohistochemical analysis of tumor
microenvironment immune status in esophageal squamous cell
carcinoma. Oncotarget 7: 47252‑47264, 2016.
22. Elston CW and Ellis IO: Pathological prognostic factors in
breast cancer. I. The value of histological grade in breast
cancer: Experience from a large study with long‑term follow‑up.
Histopathology 19: 403‑410, 1991.
23. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F,
Pruneri G, Wienert S, Van den Eynden G, Baehner FL,
Penault‑Llorca F, et al: The evaluation of tumor‑infiltrating
lymphocytes (TILs) in breast cancer: Recommendations by an
International TILs working group 2014. Ann Oncol 26: 259‑271,
2015.
24. Mohammed ZM, Going JJ, Edwards J, Elsberger B, Doughty JC
and McMillan DC: The relationship between components of
tumour inflammatory cell infiltrate and clinicopathological
factors and survival in patients with primary operable invasive
ductal breast cancer. Br J Cancer 107: 864‑873, 2012.
25. Miglietta F, Griguolo G, Guarneri V and Dieci MV: Programmed
cell death ligand 1 in breast cancer: Technical aspects, prognostic
implications, and predictive value. Oncologist 24: e1055‑e1069,
2019.
26. Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN,
Shyr Y, Moses HL, Sanders ME and Pietenpol JA: Refinement
of triple‑negative breast cancer molecular subtypes: Implications
for neoadjuvant chemotherapy selection. PLoS One 11: e0157368,
2016.
27. Harano K, Wang Y, Lim B, Seitz RS, Morris SW, Bailey DB,
Hout DR, Skelton RL, Ring BZ, Masuda H, et al: Rates of
immune cell infiltration in patients with triple‑negative breast
cancer by molecular subtype. PLoS One 13: e0204513, 2018.
28. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ,
Cachola KE, Murray JC, Tihan T, Jensen MC, et al: Loss of
tumor suppressor PTEN function increases B7‑H1 expression
and immunoresistance in glioma. Nat Med 13: 84‑88, 2007.
29. Kroemer G, Galluzzi L, Kepp O and Zitvogel L: Immunogenic
cell death in cancer therapy. Annu Rev Immunol 31: 51‑72,
2013.
30. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO
and Green AR: Tumour‑infiltrating macrophages and clinical
outcome in breast cancer. J Clin Pathol 65: 159‑163, 2012.
31. Tiainen S, Tumelius R, Rilla K, Hämäläinen K, Tammi M,
Tammi R, Kosma VM, Oikari S and Auvinen P: High numbers
of macrophages, especially M2‑like (CD163‑positive), correlate
with hyaluronan accumulation and poor outcome in breast
cancer. Histopathology 66: 873‑883, 2015.
32. Li Z, Maeda D, Yoshida M, Umakoshi M, Nanjo H, Shiraishi K,
Saito M, Kohno T, Konno H, Saito H, et al: The intratumoral
distribution influences the prognostic impact of CD68‑ and
CD204‑positive macrophages in non‑small cell lung cancer.
Lung Cancer 123: 127‑135, 2018.
33. Ichimura T, Abe H, Morikawa T, Yamashita H, Ishikawa S,
Ushiku T, Seto Y and Fukayama M: Low density of CD204‑positive
M2‑type tumor‑associated macrophages in Epstein‑Barr
virus‑associated gastric cancer: A clinicopathologic study with
digital image analysis. Hum Pathol 56: 74‑80, 2016.
34. Yagi T, Baba Y, Okadome K, Kiyozumi Y, Hiyoshi Y, Ishimoto T,
Iwatsuki M, Miyamoto Y, Yoshida N, Watanabe M, et al:
Tumour‑associated macrophages are associated with poor prog‑
nosis and programmed death ligand 1 expression in oesophageal
cancer. Eur J Cancer 111: 38‑49, 2019.
35. Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R,
Pusztai L, Pathiraja K, Aktan G, Cheng JD, et al: Pembrolizumab
in patients with advanced triple‑negative breast cancer: Phase Ib
KEYNOTE‑012 study. J Clin Oncol 34: 2460‑2467, 2016.
36. Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A,
Cescon DW, Iwata H, Campone M, Nanda R, et al: Pembrolizumab
monotherapy for previously treated metastatic triple‑negative
breast cancer: Cohort A of the phase II KEYNOTE‑086 study.
Ann Oncol 30: 397‑404, 2019.
This work is licensed under a Creative Commons
Attribution-NonCommercial-NoDerivatives 4.0
International (CC BY-NC-ND 4.0) License.
...
論文の公開元へ
